Furthermore, the upregulation of PTEN in melanoma and prostate cancer tumor models led to an increase in efficacy of anti-programmed cell death protein 1 therapy, highlighting the potential benefits that activating oligonucleotides can have in the clinical oncology field.85 This evidence concerns the gene PTEN and prostate carcinoma.